Polish bioinformatics startup Intelliseq, which specializes in the automated analysis and interpretation of variations in the human genome sequence, has secured €4.5 million in funding led by Vinci HiTech, with support from Unfold.vc, as Vestbee was told.
- Established in 2014 by Klaudia Szklarczyk-Smolana, Marcin Piechota, Michał Korostyński, and Sławomir Gołda, Intelliseq develops advanced technologies for genome analysis and genetic diagnostics.
- Their flagship platform, iFlow, enables laboratories to create customizable workflows that streamline diagnostic processes, making them faster, more accurate, and accessible.
- Intelliseq develops bioinformatics tools that automate DNA analysis, improving the efficiency and accuracy of genetic diagnostics.
- The company partners with organizations like the Metrodora Institute and DNAnexus to create tools for assessing genetic predispositions to conditions such as chronic fatigue syndrome, long COVID, somatic cancers, and hereditary diseases.
Details of the deal
- The fresh funding was led by Vinci HiTech, managed by Vinci S.A., a venture capital fund that invests in early-stage and mature enterprises across sectors such as automotive, space, energy, IT, and more.
"Intelliseq is already generating revenue in the U.S. and has a solid foundation for further expansion. We see significant growth potential in this investment and a real opportunity for an attractive exit in the future. The genomics sector is evolving rapidly, and the valuations of industry leaders like Illumina demonstrate its immense potential. This investment is both strategically and financially justified," explains Luiza Nowacka, Investment Manager at Vinci S.A..
- The investment also received support from Wroclaw-based Unfold.vc, which typically invests between €100,000 and €200,000 in technological projects, along with backing from a group of renowned private investors, including Tadeusz Wesołowski, founder of Prosper S.A.
- Intelliseq will use the fresh funds to expand into the US market, enhance its genomic technologies, and deploy its tools in diagnostic laboratories. The funding will support the development of predictive algorithms and the transition from traditional medicine to preventive healthcare.
"Our priority is the continued commercialization and global deployment of advanced genome analysis tools. We see a growing demand for scalable bioinformatics solutions, especially in the US, where the molecular diagnostics market is expanding rapidly," CEO of Intelliseq, Klaudia Szklarczyk-Smolana, commented in a press release.
